High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas

Cancer Treatment Reviews

Volumn 21, Issue 1, 1995, Pages 3-32

  Stahel, Rolf A ^a   Jost, Lorenz M ^a   Pichert, Gabriella ^a   Widmer, Lucas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW PURGING; CARDIOMYOPATHY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; IMMUNOPATHOLOGY; INFERTILITY; LEUKOENCEPHALOPATHY; LUNG FUNCTION; LYMPHOMA; META ANALYSIS; MORTALITY; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; POLYMERASE CHAIN REACTION; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SURVIVAL; SYMPTOM; VEIN OCCLUSION; WHOLE BODY RADIATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LYMPHOMA, NON-HODGKIN; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T;

EID: 0028928833     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(95)90009-8     Document Type: Article

References (150)

1. Dose: a critical factor in cancer chemotherapy
2. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma
3. Treatment of patients with aggressive lymphomas an overview
4. Increasing incidence of Non Hodgkin's lymphoma
5. The Non Hodgkin's Lymphoma Pathologic Classification Project
6. Follicular low-grade Non Hodgkin's lymphoma: long term outcome with or without tumor progression
7. The natural history of initally untreated low-grade Non Hodgkin's lymphomas
8. Histologic porgression in Non Hodgkin's lymphoma
9. Follicular lymphoma: Prognostic factors for response and survival
10. The treatment of advanced stage favorable histology non Hodkin's lymphoma: A preliminiary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation
11. The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment
12. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease
13. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-c and dexamethasone (DHAP)
14. A predictive model for aggressive non-Hodgkin's lymphoma
15. Multivariate analysis of prognostic factors in stage IV follicular low grade lymphoma: a risk model
16. Can we identify patients with low grade lymphoma for frontline ABMT?
17. Survival after relapse of low grade Non Hodgkin's lymphoma: Implications for marrow transplantation
18. Bone marrow auto-transplantation in man: Report of an International Cooperative Study
19. Autologous bone marrow transplants: different indications in Europe and in North America
20. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell Non Hodgkin's lymphoma
21. Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma:
22. High-dose therapy followed by autologous hematopoietic rescue for follicular low grade non-Hodgkin's lymphoma
23. Bone marrow transplantation in low-grade non-Hodgkin's lymphoma
24. Feasibility of autologous bone marrow transplantation for early consolidation of follicular non-Hodgkin's lymphoma
25. Cloning of the chromosome breakpoint of neoplastic B-cells with the t(14;18) translocation
26. Detection of residual lymphoma cells polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow
27. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
28. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique
29. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
30. Gene marking to trace origin of relapse after autologous bone-marrow transplantation
31. Combination sequential chemotherapy in advanced reticulum cell sarkoma
32. Advanced diffuse histiocytic lymphoma, a potentially curable disease
33. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma
34. Comparison of a standard regimen (CHOP) with tree intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma
35. Comparison of a second generation combination regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
36. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has high risk disease
37. Clinical, biological, and histologic features of late relapses in diffuse large cell lymphomas
38. Treatment of non-Hodgkin's lymphoma
39. Experience with salvage regimens at M.D. Anderson Hospital
40. Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas
41. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4 year follow-up study
42. Autologous transplantation for malignant lymphoma: a report of 101 cases from Seattle
43. Massive chemotherapy with autologous bone marrow transplantation in 50 cases of bad prognosis non-Hodgkin's lymphoma
44. Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy
45. Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still response to conventional dose therapy
46. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
47. Autologous bone marrow transplantation for non-Hodgkin's lymphoma
48. Involved field radiation, fractionated total body irradiation, high dose cyclophosphamide, and autologous bone marrow transplantation in the treatment of malignant lymphomas
49. The role of autologous bone marrrow tranplantation in 46 adult patients with non-Hodgkin's lymphomas
50. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
51. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and bone marrow transplantation
52. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma
53. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma
54. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment related mortality in 100 patients in sensitive relapse
55. Parma International Protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
56. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors
57. IMVP-16 followed by high dose chemotherapy and autologous bone marrow transplantation as salvage treatment for malignant lymphoma
58. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etopside, and cyclophosphamide and autologous bone marrow transplantation
59. One hunderd autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretreatment disease status for predicting outcome
60. Salvage chemotherapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first line CHOP
61. Outcome of patients with relapse or refractory non-Hodgkin's lymphoma referred for autologous bone marrow transplantation
62. Treatment of relapsed non-Hodgkin's lymphoma with dexamethason, high dose cytarabine, and cisplatin before marrow transplantation
63. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH84 regimen
64. The PARMA international randomized prospective study in relapsed non-Hodgkin lymphoma: second interim analysis of 172 patients
65. Induction of graft-versus-host-disease after autologous bone marrow transplantation
66. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma
67. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review
68. High dose therapy and autologous bone marrow transplantation in partial response after first line induction therapy for diffuse NHL
69. Autologous bone marrow transplantation for patients with poor prognosis lymphoma
70. Small non-cleaved lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia
71. Lymphoblastic lymphoma in adults
72. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission
73. Autologous bone marrow transplantation for adult advanced stage lymphoblastic lymphoma in first CR
74. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation
75. Autologous bone marrow transplantation for adult poor-risk lymphoblastic lymphoma in first remission
76. High dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study
77. Fünf Jahre Dosisintensivierung mit Rücktransfusion autologer Knochenmark- oder peripherer Stammzellen bei malignen Lymphomen mit hohem Rezidivrisiko
78. High dose chemotherapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma the EBMT experience
79. Autologous bone marrow transplantation in 22 adult patients with lymphoblastic lymphoma responsive to conventional dose chemotherapy
80. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy in first complete remission aggressive non-Hodgkin's Lymphoma (NHL): 1st. interim analysis on 370 patients (LNH87 Protocol)
81. 5-year update of the Milan Cancer Institute randomized trial of high dose sequential versus MACOP-B therapy for diffuse large cell lymphomas
82. Autologous hematopoietic stem cell transplantation in intermediate and high grade nonHodgkin's lymphoma: a review
83. Autologous transplantation for malignant lymphoma: a report of 101 cases from Seattle
84. Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma
85. Autologous bone marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle
86. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide
87. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group data registry
88. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
89. Autologous transplantation with peripheral blood stem cells: a review of clinical results
90. A randomized study of recombinant human granulocyte colony stimulating factor (filgrastim) after high dose chemotherapy and autologous bone marrow transplantation for high risk lymphomas
91. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma
92. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging
93. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
94. Molecular detection of residual lymphoma cells in peripheral blood stem cell harvest and following autologous transplantation
95. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
96. Ex vivo expansion of enriched peripheral blood CD34 (+) positive progenitor cells by stem cell factor, interleukin-1β, interleukin-6, interleukin-3, interferon-γ, and erytropoietin
97. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the EBMT lymphoma registry
98. High-dose chemotherapy, fractionated total-body irradiation, and allogeneic marrow transplantation for malignant lymphoma
99. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant
100. Acute lung injury following treatment with high dose cyclophosphamide, cisplatin, and carmustin: Pharmacodynamic evaluation of carmustin
101. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant
102. Second cancers among long term survivors of non-Hodkgin's lymphoma
103. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer chemotherapy
104. Myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma: the price of progress?
105. Gondadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma
106. Hodgkin's disease
107. Drug Therapy: Hodgkin's disease
108. Twenty years of MOPP therapy for Hodgkin's disease
109. ChIVPP combination chemotherapy for Hodgkin's disease: long term results
110. Salvage chemotherapy with ABVD in MOPPresistant Hodgkin's disease
111. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease
112. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP
113. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
114. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: The Milan experience
115. A randomized trial of MOPP/ABV hybrid versus sequential MOPP-ABVD in advanced Hodgkin's disease
116. Twenty years of MOPP therapy for Hodgkin's disease
117. Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin
118. Prognostic factors for survival in stage IIB and VI Hodgkin's disease: A multivariate analysis comparing two specialist treatment centers
119. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy
120. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy
121. Management of relapse and survival in advanced stage Hodgkin's disease: The EORTC experience
122. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability of cure
123. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe
124. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988
125. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease
126. Allogeneic bone marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease
127. High-dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease
128. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease
129. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation
130. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation
131. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodkgin's disease
132. Prognostic factors and survival after high-dose cyclophosphamide, carmustin, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease
133. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease
134. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease
135. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer center experience using high dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation
136. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
137. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease
138. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant
139. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease
140. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients
141. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience
142. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease
143. Intensive therapy with cyclophosphamide carmustine etoposide+-cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy
144. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
145. Autologous transplantation for Hodgkin's disease: coming of age?
146. Autologous bone marrow tranplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol
147. The Stanford experience with-high dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data
148. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodkgin's disease
149. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease